A Phase 3 trial designed to find out if adding ipilimumab (Yervoy) to Keytruda would improve the outlook for patients with non-small cell lung cancer has failed. As a result, Keytruda (pembrolizumab) monotherapy is still the better option for treating the disease, according to Merck & Co Inc.
